Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Buy
75
VERA Quote, Financials, Valuation and Earnings
Last price:
$44.83
Seasonality move
:
31.1%
Day range:
$43.35 - $46.18
52-week range:
$18.53 - $49.77
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
7.20x
Volume:
2.5M
Avg. volume:
1.8M
1-year change:
-6.67%
Market cap:
$2.9B
Revenue:
--
EPS (TTM):
-$3.99
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
VERA
Vera Therapeutics, Inc.
|
-- | -$1.25 | -- | -74.71% | $67.46 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$974.1M | $1.75 | 97.59% | -58.59% | $492.17 |
|
INSM
Insmed, Inc.
|
$115.5M | -$1.37 | 64.56% | -3.9% | $222.78 |
|
KRYS
Krystal Biotech, Inc.
|
$120.3M | $1.12 | 16.27% | 5.57% | $217.70 |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$247.7M | -$1.99 | 201.43% | -81.62% | $563.80 |
|
OLMA
Olema Pharmaceuticals, Inc.
|
-- | -$0.45 | -- | -21.07% | $36.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
VERA
Vera Therapeutics, Inc.
|
$44.90 | $67.46 | $2.9B | -- | $0.00 | 0% | -- |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$458.12 | $492.17 | $60.5B | 1,904.86x | $0.00 | 0% | 18.79x |
|
INSM
Insmed, Inc.
|
$204.00 | $222.78 | $43.5B | -- | $0.00 | 0% | 86.81x |
|
KRYS
Krystal Biotech, Inc.
|
$234.13 | $217.70 | $6.8B | 35.12x | $0.00 | 0% | 18.72x |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$577.30 | $563.80 | $13.1B | -- | $0.00 | 0% | 17.29x |
|
OLMA
Olema Pharmaceuticals, Inc.
|
$27.21 | $36.50 | $1.9B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
VERA
Vera Therapeutics, Inc.
|
16.22% | 2.262 | 4.16% | 11.88x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
92.22% | 1.279 | 4.61% | 2.37x |
|
INSM
Insmed, Inc.
|
44.07% | 2.512 | 2.43% | 4.18x |
|
KRYS
Krystal Biotech, Inc.
|
0.83% | 0.141 | 0.19% | 9.43x |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
35.63% | -0.048 | 3.33% | 3.14x |
|
OLMA
Olema Pharmaceuticals, Inc.
|
1.44% | 1.569 | 0.67% | 7.90x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
VERA
Vera Therapeutics, Inc.
|
-$564K | -$83.9M | -48.69% | -55.53% | -- | -$62M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1B | $368M | 1.51% | 31.15% | 29.46% | $313M |
|
INSM
Insmed, Inc.
|
$111.4M | -$261.4M | -70.98% | -193.23% | -183.61% | -$222.2M |
|
KRYS
Krystal Biotech, Inc.
|
$92.1M | $41.4M | 19.74% | 19.91% | 42.31% | $38M |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$268.8M | -$114M | -32.91% | -40.56% | -39.68% | $76M |
|
OLMA
Olema Pharmaceuticals, Inc.
|
-$43K | -$45.9M | -45.23% | -45.61% | -- | -$34.5M |
Vera Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns VERA or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Vera Therapeutics, Inc.'s net margin of 20.1%. Vera Therapeutics, Inc.'s return on equity of -55.53% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.
Company Gross Margin Earnings Per Share Invested Capital VERAVera Therapeutics, Inc.-- -$1.26 $476.1M ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B -
What do Analysts Say About VERA or ALNY?
Vera Therapeutics, Inc. has a consensus price target of $67.46, signalling upside risk potential of 50.25%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $492.17 which suggests that it could grow by 7.43%. Given that Vera Therapeutics, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Vera Therapeutics, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VERAVera Therapeutics, Inc.10 2 0 ALNYAlnylam Pharmaceuticals, Inc.14 7 0 -
Is VERA or ALNY More Risky?
Vera Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.301, suggesting its less volatile than the S&P 500 by 69.879%.
-
Which is a Better Dividend Stock VERA or ALNY?
Vera Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vera Therapeutics, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VERA or ALNY?
Vera Therapeutics, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. Vera Therapeutics, Inc.'s net income of -$80.3M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, Vera Therapeutics, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,904.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vera Therapeutics, Inc. is -- versus 18.79x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VERAVera Therapeutics, Inc.-- -- -- -$80.3M ALNYAlnylam Pharmaceuticals, Inc.18.79x 1,904.86x $1.2B $251.1M
-
Which has Higher Returns VERA or INSM?
Insmed, Inc. has a net margin of -- compared to Vera Therapeutics, Inc.'s net margin of -259.95%. Vera Therapeutics, Inc.'s return on equity of -55.53% beat Insmed, Inc.'s return on equity of -193.23%.
Company Gross Margin Earnings Per Share Invested Capital VERAVera Therapeutics, Inc.-- -$1.26 $476.1M INSMInsmed, Inc.78.29% -$1.75 $1.7B -
What do Analysts Say About VERA or INSM?
Vera Therapeutics, Inc. has a consensus price target of $67.46, signalling upside risk potential of 50.25%. On the other hand Insmed, Inc. has an analysts' consensus of $222.78 which suggests that it could grow by 9.21%. Given that Vera Therapeutics, Inc. has higher upside potential than Insmed, Inc., analysts believe Vera Therapeutics, Inc. is more attractive than Insmed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VERAVera Therapeutics, Inc.10 2 0 INSMInsmed, Inc.17 1 0 -
Is VERA or INSM More Risky?
Vera Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.49%.
-
Which is a Better Dividend Stock VERA or INSM?
Vera Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vera Therapeutics, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VERA or INSM?
Vera Therapeutics, Inc. quarterly revenues are --, which are smaller than Insmed, Inc. quarterly revenues of $142.3M. Vera Therapeutics, Inc.'s net income of -$80.3M is higher than Insmed, Inc.'s net income of -$370M. Notably, Vera Therapeutics, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vera Therapeutics, Inc. is -- versus 86.81x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VERAVera Therapeutics, Inc.-- -- -- -$80.3M INSMInsmed, Inc.86.81x -- $142.3M -$370M
-
Which has Higher Returns VERA or KRYS?
Krystal Biotech, Inc. has a net margin of -- compared to Vera Therapeutics, Inc.'s net margin of 81.15%. Vera Therapeutics, Inc.'s return on equity of -55.53% beat Krystal Biotech, Inc.'s return on equity of 19.91%.
Company Gross Margin Earnings Per Share Invested Capital VERAVera Therapeutics, Inc.-- -$1.26 $476.1M KRYSKrystal Biotech, Inc.94.21% $2.66 $1.1B -
What do Analysts Say About VERA or KRYS?
Vera Therapeutics, Inc. has a consensus price target of $67.46, signalling upside risk potential of 50.25%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $217.70 which suggests that it could fall by -4.75%. Given that Vera Therapeutics, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Vera Therapeutics, Inc. is more attractive than Krystal Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VERAVera Therapeutics, Inc.10 2 0 KRYSKrystal Biotech, Inc.9 1 0 -
Is VERA or KRYS More Risky?
Vera Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.528%.
-
Which is a Better Dividend Stock VERA or KRYS?
Vera Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vera Therapeutics, Inc. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VERA or KRYS?
Vera Therapeutics, Inc. quarterly revenues are --, which are smaller than Krystal Biotech, Inc. quarterly revenues of $97.8M. Vera Therapeutics, Inc.'s net income of -$80.3M is lower than Krystal Biotech, Inc.'s net income of $79.4M. Notably, Vera Therapeutics, Inc.'s price-to-earnings ratio is -- while Krystal Biotech, Inc.'s PE ratio is 35.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vera Therapeutics, Inc. is -- versus 18.72x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VERAVera Therapeutics, Inc.-- -- -- -$80.3M KRYSKrystal Biotech, Inc.18.72x 35.12x $97.8M $79.4M
-
Which has Higher Returns VERA or MDGL?
Madrigal Pharmaceuticals, Inc. has a net margin of -- compared to Vera Therapeutics, Inc.'s net margin of -39.75%. Vera Therapeutics, Inc.'s return on equity of -55.53% beat Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56%.
Company Gross Margin Earnings Per Share Invested Capital VERAVera Therapeutics, Inc.-- -$1.26 $476.1M MDGLMadrigal Pharmaceuticals, Inc.93.57% -$5.08 $972.1M -
What do Analysts Say About VERA or MDGL?
Vera Therapeutics, Inc. has a consensus price target of $67.46, signalling upside risk potential of 50.25%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $563.80 which suggests that it could fall by -2.34%. Given that Vera Therapeutics, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Vera Therapeutics, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VERAVera Therapeutics, Inc.10 2 0 MDGLMadrigal Pharmaceuticals, Inc.13 1 0 -
Is VERA or MDGL More Risky?
Vera Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -1.034, suggesting its less volatile than the S&P 500 by 203.399%.
-
Which is a Better Dividend Stock VERA or MDGL?
Vera Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vera Therapeutics, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VERA or MDGL?
Vera Therapeutics, Inc. quarterly revenues are --, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $287.3M. Vera Therapeutics, Inc.'s net income of -$80.3M is higher than Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M. Notably, Vera Therapeutics, Inc.'s price-to-earnings ratio is -- while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vera Therapeutics, Inc. is -- versus 17.29x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VERAVera Therapeutics, Inc.-- -- -- -$80.3M MDGLMadrigal Pharmaceuticals, Inc.17.29x -- $287.3M -$114.2M
-
Which has Higher Returns VERA or OLMA?
Olema Pharmaceuticals, Inc. has a net margin of -- compared to Vera Therapeutics, Inc.'s net margin of --. Vera Therapeutics, Inc.'s return on equity of -55.53% beat Olema Pharmaceuticals, Inc.'s return on equity of -45.61%.
Company Gross Margin Earnings Per Share Invested Capital VERAVera Therapeutics, Inc.-- -$1.26 $476.1M OLMAOlema Pharmaceuticals, Inc.-- -$0.49 $312M -
What do Analysts Say About VERA or OLMA?
Vera Therapeutics, Inc. has a consensus price target of $67.46, signalling upside risk potential of 50.25%. On the other hand Olema Pharmaceuticals, Inc. has an analysts' consensus of $36.50 which suggests that it could grow by 34.14%. Given that Vera Therapeutics, Inc. has higher upside potential than Olema Pharmaceuticals, Inc., analysts believe Vera Therapeutics, Inc. is more attractive than Olema Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VERAVera Therapeutics, Inc.10 2 0 OLMAOlema Pharmaceuticals, Inc.8 0 0 -
Is VERA or OLMA More Risky?
Vera Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Olema Pharmaceuticals, Inc. has a beta of 1.870, suggesting its more volatile than the S&P 500 by 86.967%.
-
Which is a Better Dividend Stock VERA or OLMA?
Vera Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Olema Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vera Therapeutics, Inc. pays -- of its earnings as a dividend. Olema Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VERA or OLMA?
Vera Therapeutics, Inc. quarterly revenues are --, which are smaller than Olema Pharmaceuticals, Inc. quarterly revenues of --. Vera Therapeutics, Inc.'s net income of -$80.3M is lower than Olema Pharmaceuticals, Inc.'s net income of -$42.2M. Notably, Vera Therapeutics, Inc.'s price-to-earnings ratio is -- while Olema Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vera Therapeutics, Inc. is -- versus -- for Olema Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VERAVera Therapeutics, Inc.-- -- -- -$80.3M OLMAOlema Pharmaceuticals, Inc.-- -- -- -$42.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
